ClinicalTrials.gg
CompletedNCT03001622Updated Sep 19, 2017

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 interventional study of IFX-1 in Hidradenitis Suppurativa, sponsored by InflaRx GmbH. Completed at 1 site in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-19.

Sponsored by InflaRx GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Hidradenitis Suppurativa with a site in Greece — 3 open to participants now, 10 under way, 6 of them phase 3. Hidradenitis Suppurativa · Greece.

Enrollment
28th of 29
12 · median 214
Started
2016
with 2 others
Phase 2
15 of 31
1 open now
Registered
6th of 31
by date
Lead sponsor
3 of 31
InflaRx GmbH

Among the 31 studies in Hidradenitis Suppurativa with a site in Greece, this one is the 28th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2016, is one of 15 in phase 2, and was the 6th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 31 studies in Hidradenitis Suppurativa with a site in Greece are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Hidradenitis Suppurativa with a site in Greece, or all of them as a file.
02

Study summary

The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients. In addition the trial aims to characterize the pharmacokinetics and pharmacodynamics of IFX-1 as well as to generate preliminary data on the efficacy of IFX-1 on clinical endpoints (e.g., Hidradenitis Suppurativa Clinical Response (HiSCR), Dermatology Life Quality Index (DLQI), Visual Analog Scale (VAS) for disease, VAS for pain, Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA), Modified Sartorius Score (mSS)).

03

Conditions studied

  • Hidradenitis Suppurativa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years old
  2. Written
  3. Diagnosis of HS for at least 1 year
  4. Hidradenitis suppurativa (HS) lesions in at least 2 distinct anatomic areas, one of which is Hurley Stage II or III
  5. Total AN (abscesses and nodules) count ≥3
  6. Patients with either primary or secondary failure of biological treatment or are not eligible for treatment with other biologicals
  7. Failure of previous antimicrobial treatments

Exclusion criteria

Exclusion Criteria:

  1. Body weight above 150 kg or body weight below 60 kg
  2. Has a draining fistula count of greater than 30 at baseline
  3. Surgical management planned within the next 24 weeks
  4. Occurrence of a flare-up of HS leading to intravenous antimicrobial treatment within the last 14 days
  5. Any other disease and condition that is likely to interfere with evaluation of study product, outcome assessment or satisfactory conduct of the study

    1. Active infection
    2. Severe congestive heart failure (i.e., (NYHA) Class IV)
    3. Depression
    4. History of systemic lupus erythematosus or rheumatoid arthritis
    5. Any immunodeficiency disease
    6. Active hematological or solid malignant tumor
    7. Patients must not have had any other active skin disease or condition (e.g., bacterial, fungal, or viral infection) that may have interfered with assessment of HS.
  6. One of the following abnormal laboratory results

    1. White blood cell count \< 2,500/mm3
    2. \< 1000/mm3
    3. Serum Creatinine > 3 x Upper Normal Limit (UNL)
    4. Total > 2 x UNL
    5. Alanine-Aminotransferase (ALAT) > 2 x UNL
    6. Positive screening test for , , or 1/2
  7. Prior administration of any biological compound in the last 3 months
  8. Intake of defined as daily intake of prednisone or equivalent more than 1 mg/kg for the last three weeks;
  9. Intake of drugs within past 30 days (e.g., cyclosporine, tacrolimus)
  10. General exclusion criteria

    1. Pregnant (in women of an urine pregnancy test has to be performed) or breast-feeding women
    2. Women with childbearing potential (defined as within two years of their last menstruation) not willing to practice appropriate measures (e.g., implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy, abstinence) while participating in the trial
    3. Participation in any interventional clinical trial within the last three months
    4. Known intravenous drug abuse
    5. Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub-investigators, or study nurse) or relationship to the sponsor
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Other
    IFX-1

    Biological: IFX-1

Interventions

  • BiologicalIFX-1

    chimeric, monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Number of patients with at least possibly related treatment-emergent adverse events (TEAEs)

    Time frame: up to Day 134

  2. Number of patients with detection of anti-drug antibodies (pre-/post-dosing)

    Time frame: up to Day 134

Secondary outcomes

  1. Plasma concentration of IFX-1

    Time frame: From Day 1 until Day 134

  2. Plasma concentration of C5a

    Time frame: Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134

  3. Percentage change from baseline in total abscess and nodule (AN) count per time point

    Time frame: Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134

  4. Hidradenitis Suppurativa Clinical Response (HiSCR) per time point

    Time frame: Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134

  5. Achievement of Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA) of clear, minimal, or mild among patients with at least 2 grades improvement (reduction) from baseline

    Time frame: Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134

  6. HS-PGA score per time point

    Time frame: Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134

  7. Achievement of at least a 30% reduction and at least a 10 mm reduction in the Visual Analog Scale (VAS) for pain, among patients who had a baseline pain assessment ≥ 30 mm

    Time frame: At each visit from Day 1 until Day 134

  8. VAS pain score per time point

    Time frame: At each visit from Day 1 until Day 134

  9. Change from baseline in VAS pain score per time point

    Time frame: At each visit from Day 1 until Day 134

  10. VAS disease score per time

    Time frame: At each visit from Day 1 until Day 134

  11. Change from baseline in VAS disease score per time point

    Time frame: At each visit from Day 1 until Day 134

  12. Dermatology Life Quality Index (DLQI) per time point

    Time frame: Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134

  13. Change from baseline in DLQI per time point

    Time frame: Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134

07

Study locations

1 site
  • ATTIKON University Hospital
    Athens, 12462, Greece
08

References and documents

Publications

  • Prens LM, Ardon CB, van Straalen KR, van der Zee HH, Seelen MAJ, Laman JD, Prens EP, Horvath B, Damman J. No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa. J Invest Dermatol. 2021 Dec;141(12):2966-2969.e1. doi: 10.1016/j.jid.2021.03.037. Epub 2021 Jul 9. No abstract available. PubMed 34252397 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jul 2017, 7 months.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 7 months is below that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2016
First posted
Dec 23, 2016
StartActual
Dec 2016
Primary completionActual
Jul 2017
CompletionActual
Jul 2017
Last update
Sep 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03001622
Lead sponsor
InflaRx GmbH
Responsible party
Sponsor
First posted
Dec 23, 2016
Start date
Dec 2016
Primary completion
Jul 2017
Completion
Jul 2017
Last update
Sep 19, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilobelimab

Start the discussion